Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.15 – $10.43
47% from low
Exchange
OTC Link
OS
Borrow rate
0.86%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.5M | $216.4M | $556.6M | $893.6M | $1.02B | $1.05B | $1.14B | $1.18B |
| Cost of revenue | $29.8M | $109.4M | $252.4M | $401.6M | $513.4M | $528.1M | $536.0M | $600.4M |
| Gross profit | $32.7M | $107.0M | $304.2M | $491.9M | $504.0M | $526.5M | $601.1M | $574.9M |
| Gross margin | 52.3% | 49.5% | 54.7% | 55.1% | 49.5% | 49.9% | 52.9% | 48.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$27.5M | −$25.0M | $106.1M | $124.4M | $121.1M | $184.6M | $224.4M | $140.1M |
| EBITDA | $35.3M | $2.2M | $204.6M | $328.6M | $217.3M | $281.0M | $224.4M | $485.0M |
| Net income | −$7.9M | −$59.5M | $15.0M | $75.4M | $12.0M | $36.3M | $73.1M | $116.2M |
| Net margin | -12.6% | -27.5% | 2.7% | 8.4% | 1.2% | 3.4% | 6.4% | 9.9% |
| EPS (diluted) | -0.06 | -0.31 | 0.07 | 0.33 | 0.05 | 0.15 | 0.30 | 0.49 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.2B | $0.13 | $0.07–$0.21 | 3 |
| 2027 | $1.3B | $0.15 | $-0.01–$0.22 | 5 |
| 2028 | $1.4B | $0.28 | $0.27–$0.28 | 2 |
| 2029 | $1.4B | $0.27 | $0.27–$0.28 | 1 |
Forward consensus · source: Financial Modeling Prep
GREEN THUMB INDUS SUB VTG
No one on the platform currently holds GTBIF.
No tracked institution reports a position in GTBIF as of their last filing.
No one on the platform has traded GTBIF yet.
| -5.28% |
| $1.1B |
| — |
| KSPHFKissei Pharmaceutical Co., Ltd. | $30.28 | +17.50% | $1.3B | — |
| NPNKFNippon Shinyaku Co., Ltd. | $32.75 | +4.30% | $2.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MSOS $TRLV $GTBIF $HITI $CURLD There is an old adage on Wall Street that says “the longer the base the higher in space” And that just means that a long base leads to a much longer and stronger move when it does finally begin. The second key technical indicator we see here is that “volume precedes price” This is a core technical analysis principle stating that changes in trading volume signal impending price movements. Generational wealth setup for those who have the patience.
View on StockTwits ↗$CURLD $MSOS $GTBIF $TRLV $TLRY https://www.youtube.com/live/EOJrdwfzA4Y?is=BNg3JwvglovBqJy2
View on StockTwits ↗$GTBIF https://www.marijuanamoment.net/dea-and-fda-highlight-how-marijuana-is-safer-than-alcohol-and-opioids-during-rescheduling-hearings-opening-day/
View on StockTwits ↗3 Reasons to Buy Green Thumb Industries Stock Hand Over Fist: https://www.fool.com/investing/2026/06/28/3-reasons-to-buy-green-thumb-industries-stock-hand/ $GTBIF
View on StockTwits ↗$GTBIF The Virginia Senate & House accepted Gov. Abigail Spanberger's amendments to a budget bill containing provisions to legalize recreational marijuana sales—meaning it has now been formally enacted into law without requiring any additional action from the governor.
View on StockTwits ↗$GTBIF https://www.marijuanamoment.net/dea-and-fda-highlight-how-marijuana-is-safer-than-alcohol-and-opioids-during-rescheduling-hearings-opening-day/ vb
View on StockTwits ↗$GTBIF $7.47 ask. BUY/NEW LONG POSITION carries SPM 87.07 tag to $15.00 in midterm
View on StockTwits ↗$HITI Europe: More Than Just Germany Many investors still view Remexian as a German acquisition. I don't. Since acquiring Remexian, High Tide has: 🟢 Increased German medical cannabis market share from ~5% to ~14% 🟢 Successfully resolved major procurement challenges 🟢 Recovered gross margins to 27% 🟢 Secured exclusive supply agreements with leading Canadian LPs 🟢 Established itself as one of Germany's leading medical cannabis distributors Germany is already Europe's largest medical cannabis market. Management has repeatedly highlighted the UK as its next strategic opportunity, with independent forecasts projecting a medical cannabis market of ~£900M by 2030. France, Poland and other European markets are gradually opening as well. To me, High Tide didn't buy Germany. It bought a gateway into Europe. $HITI $MSOS $GTBIF $TRLV
View on StockTwits ↗$GTBIF buy the best balance sheet in the sector keep buying and accumulating this stock will be $20+ very soon
View on StockTwits ↗$HITI Procurement: The Most Overlooked Competitive Advantage? Most investors compare cannabis companies by: • Revenue • EBITDA • Store count But mature industries often reward something else. 🟢 Costco didn't become successful because it produced food. 🟢 Walmart doesn't manufacture consumer goods. 🟢 McKesson doesn't invent pharmaceuticals. They control purchasing power. The larger the purchasing volume... 🟢 the better the prices 🟢 the stronger the supplier relationships 🟢 the greater the product selection 🟢 the higher the potential margin Raj Grover rarely talks about becoming the largest grower. Instead, he repeatedly talks about procurement and building the largest cannabis menu. Could procurement become one of High Tide's biggest competitive advantages? Next: Why Europe could be much bigger than most investors expect. $HITI $MSOS $GTBIF $TRLV
View on StockTwits ↗$HITI Follow The Money One of the best ways to understand a company is to ignore what management says... ...and look at where they allocate capital. Over the past few years, Raj Grover acquired: 🟢 Smoke Cartel 🟢 Daily High Club 🟢 NuLeaf Naturals 🟢 FAB CBD 🟢 DankStop 🟢 Remexian Now ask yourself: What do these companies have in common? Not cultivation. Not greenhouses. Not production. Instead, they strengthened: 🟢 Customer access 🟢 E-commerce 🟢 Distribution 🟢 Procurement 🟢 Europe One acquisition after another follows the same direction. Whether that strategy ultimately succeeds remains to be seen. But it doesn't look random. It looks intentional. Next: Why procurement may become more valuable than cultivation. $HITI $MSOS $GTBIF $TRLV
View on StockTwits ↗$HITI The High Tide Research Series part one of many Most investors still value $HITI as a Canadian cannabis retailer. I think that's becoming an outdated way to look at the company. Today's High Tide is building several businesses simultaneously: 🟢 Canada's largest cannabis retail network by store count 🟢 Europe's fastest-growing medical cannabis distributor through Remexian 🟢 One of the industry's largest cannabis loyalty ecosystems 🟢 Procurement-first business model instead of cultivation 🟢 Growing White Label strategy 🟢 Global CBD & e-commerce ecosystem The question is no longer: "How many stores does High Tide own?" The better question is: "What business is High Tide becoming?" This series isn't about hype. It's about understanding the strategy Raj Grover has been building for years. Next: Why procurement may ultimately become more valuable than cultivation. $HITI $MSOS $GTBIF $TRLV $VRNO
View on StockTwits ↗$GTBIF so Indiana, Idaho, and Nebraska…none should receive any tax money from weed sales. They should be required to hand that shit directly to the people.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 36.3× earnings vs its 56.7× historical median P/E.
Fair value ≈ $11.93 · price $7.64 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.